Abrégé

The present invention relates to a lipid-based formulation for topical ophthalmic use to increase the bioavailability of antibiotics in intraocular tissues, wherein said formulation comprises: Moxifloxacin (M), polyethylene glycol (PEG)-12 glyceryl dimyristate and ethyl alcohol, polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15), anhydrous citric acid and sodium citrate dihydrate. The compositions of the invention contain an effective amount of moxifloxacin (M), 0.001 to 1 mg, in other words, 0.0001 to 0.1% (w/v), polyethylene glycol (PEG)-12 glyceryl dimyristate which is used as a structural component of liposomes in a concentration of 5-15% (w/v) and ethyl alcohol which is used as an organic solvent in a concentration of 0.7 to 2.1% (v/v). Furthermore, the formulation contains 2.5 to 7.5% (w/v) of polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15) as a non-ionic solubiliser and emulsifying agent. Likewise, the aqueous compositions of the present invention optionally comprise more excipients selected from the group consisting of buffering agents, pH-adjusting agents and preservatives. Anhydrous citric acid (0.04 to 0.16%) and sodium citrate dihydrate (0.23 to 0.69%) are used as buffers.

Classes IPC  ?

• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention relates to a lipid-based formulation that increases the penetration of the eyeball by anaesthetics for topical ophthalmic use, wherein the formulation comprises: tetracaine (T), polyethylene glycol (PEG)-12 glyceryl dimyristate, ethyl alcohol, PEG(15)-hydroxystearate (Kolliphor® HS15), citric acid anhydride and sodium citrate dihydrate. The compound of the invention is characterised by low toxicity and in that it also acts as a permeability enhancer because it promotes molecule transport through the cell membranes, increasing the endocytosis rate and stimulating drug translocation via the paracellular route.

Classes IPC  ?

• A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61P 27/02 - Agents ophtalmiques
• A61P 23/00 - Anesthésiques

Abrégé

The present invention relates to a lipid-based formulation for topical ophthalmic use to increase the bioavailability of non-steroidal anti-inflammatory drugs in intraocular tissues that comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), polyethylene glycol (PEG)-12 glyceryl dimyristate, polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15), an organic solvent, and excipients selected from the group consisting of buffering agents.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61P 27/02 - Agents ophtalmiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of helenalin to the scleral tissue of the ocular surface (cornea and conjunctiva) in human beings. The invention is useful for treating dry eye syndrome (DES) owing to its anti-inflammatory activity and its ability to inhibit the action of tumour necrosis factor-alpha (TNFα) and metalloproteinase 9 (MMP-9). The lipid-based formulation has the potential to improve stability, enhance the efficiency of penetration of the natural barriers of the eyeball and increase helenalin bioavailability in the tissues of the ocular surface.

Classes IPC  ?

• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention relates to a solution for enhancing the efficiency of the penetration and bioavailability of bioactives present in jaborandi extract in the scleral tissue of the eye ball, which is based on using advanced delivery systems and methods, such as lipid-based systems. Some of these lipid systems include lipid, micellar and liposome nanoparticles. The lipid nanoparticles are aqueous colloidal dispersions comprising solid lipids as matrix material, capable of encapsulating both hydrophilic and lipophilic agents, which ultimately yield thermodynamically stable compounds, with the encapsulated agent being protected. The compounds have controlled release and are biocompatible with the barriers of the eye ball, easy to produce and able to be sterilised in an autoclave. Accordingly, the lipid-based topical ophthalmic formulation comprising jaborandi extract represents an important advancement in enhancing the efficiency of the penetration and bioavailability of the bioactives thereof in scleral tissue (iris and lens) of the human eyeball.

Classes IPC  ?

• A61K 36/75 - Rutaceae (famille de la rue)
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 27/02 - Agents ophtalmiques

Abrégé

Method and chemical formulation for treating contaminated medical waste by means of grinding and disinfection with peracetic acid. The invention relates to a peracetic-acid-based formulation and a continuous in-situ method for grinding and disinfecting, with the peracetic acid formulation, medical waste contaminated with viruses, bacteria, etc.

Classes IPC  ?

• B09B 3/35 - Déchiquetage, écrasement ou découpage
• A01N 37/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe Leurs thio-analogues
• A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
• B09B 3/60 - Traitement biochimique, p. ex. en utilisant des enzymes
• B09B 101/65 - Déchets médicaux

Abrégé

Vaccinium Myrtillus LVaccinium Myrtillus L), omega-3 fatty acids, lactoferrin, vitamins A and E and excipients with surfactant properties, for primary treatment and/or as an adjuvant for dry eye syndrome in human beings. In order to overcome the negative aspects of administering the formulation individually and to provide synergistic effects, the invention is characterised by the design of a formulation containing, among other components, polyphenols from blueberry extract, without eliminating the matrix, which promotes the bioactivity of the polyphenols present in same, as there is evidence that the presence of other polyphenols increases the bioavailability and bioactivity thereof. In addition, other elements of the matrix promote stability and absorption of polyphenols.

Classes IPC  ?

• A61K 31/07 - Composés du rétinol, p. ex. vitamine A
• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
• A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
• A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention consists of a food supplement based on a mixture of nopal, cacao and cricket contained preferably, but not exclusively, in sachets, for its primary use as an adjuvant for managing insulin resistance, reducing intestinal dysbiosis and reducing obesity in patients with some type of obesity and/or suffering from fatty liver disease of any aetiology, Crohn's disease or any other intestinal metabolic disorder. Furthermore, the food supplement can also be mixed with any type of prebiotics and/or probiotics, for its use as an adjuvant for managing malnutrition, obesity, dysbiosis and insulin resistance in patients with any type of obesity and/or suffering from fatty liver disease.

Classes IPC  ?

• A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
• A61K 36/33 - Cactaceae (famille du cactus), p. ex. figue de Barbarie ou Cereus
• A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
• A61P 3/04 - AnorexigènesMédicaments de l'obésité

Abrégé

Arnica montanaArnica montana extract and sodium hyaluronate for use to treat dry eye syndrome. The formulation improves tear film quality and modulates the inflammatory process and the symptoms associated with dry eye syndrome.

Classes IPC  ?

• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 31/728 - Acide hyaluronique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of bioactive agents contained in peppermint leaf extract to the scleral tissue of the posterior segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of the development of chronic degenerative processes in the intraocular tissues, including those of the posterior segment of the eyeball, owing to its anti-inflammatory, antiangiogenic, antifibrotic and antioxidant activity. The lipid-based formulation has the potential to improve stability, boost the efficiency of penetration of the natural barriers of the eyeball and increase polyphenol bioavailability in the intraocular tissues.

Classes IPC  ?

• A61K 36/534 - Mentha (menthe)
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 27/02 - Agents ophtalmiques

Abrégé

Disclosed is a formulation which, in association with a grinding system, transforms biohazardous wastes unto raw material for the preparation of composts, enabling biohazardous infectious waste to be inactivated for use and industrial biohazardous infectious waste to be inactivated for reuse as a protein source for producing protein products. The formulation can be used to eliminate microorganisms in waste resulting from the production of drugs and vaccines in ovo, with applications in biohazardous infectious waste and animal waste with a high protein content and decomposition potential for the preparation of composts.

Classes IPC  ?

• A61L 11/00 - Procédés de désinfection ou de stérilisation spécialement adaptés aux déchets
• A01N 37/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe Leurs thio-analogues
• A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
• B09B 3/35 - Déchiquetage, écrasement ou découpage
• B09B 3/70 - Traitement chimique, p. ex. ajustement du pH ou oxydation
• C05F 7/00 - Engrais fabriqués à partir des eaux résiduaires ou d'épandage, wagage, limon ou masses similaires
• C05F 1/00 - Engrais fabriqués à partir de cadavres d'animaux ou de parties de ceux-ci

Abrégé

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of bioactive agents contained in blueberry extract, in scleral tissue of the rear portion of the eyeball in human beings. The invention is useful for maintaining health and reducing the risk of the development of chronic degenerative processes in the intraocular tissues, including those of the rear portion of the eyeball, owing to its anti-inflammatory, antiangiogenic, anti-fibrotic and antioxidant activity. The lipid-based formulation has the potential to improve stability, improve the efficiency of penetration of the natural barriers of the eyeball and increase polyphenol bioavailability in the intraocular tissues.

Classes IPC  ?

• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention consists of a lipid-based formulation for topical ophthalmic use which functions as a delivery system for the bioactive agents contained in the hop flower extract in white tissue in the rear segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the intraocular tissue, including the tissue in the rear segment of the eyeball, due to its anti-inflammatory, neuro-protective and antioxidant activity. The object of this invention is to make available a lipid-based formulation for topical ophthalmic use which functions as a delivery system for the bioactive agents contained in the hop flower extract in white tissue in the rear segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the intraocular tissue, including the tissue in the rear segment of the eyeball, due to its anti-inflammatory, neuro-protective and antioxidant activity.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 27/02 - Agents ophtalmiques

Abrégé

Method and chemical formulation for treating contaminated medical waste by means of grinding and disinfection with peracetic acid. The invention relates to a peracetic-acid-based formulation and a continuous in-situ method for grinding and disinfecting, with the peracetic acid formulation, medical waste contaminated with viruses, bacteria, etc.

Classes IPC  ?

• A01N 37/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe Leurs thio-analogues
• A61L 11/00 - Procédés de désinfection ou de stérilisation spécialement adaptés aux déchets
• B02C 19/00 - Autres dispositifs ou procédés de désagrégation
• B09B 3/00 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif

Abrégé

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 31/733 - Fructosanes, p. ex. inuline
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61K 35/745 - Bifidobactéries
• A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
• A61K 31/4415 - Pyridoxine, c.-à-d. vitamine B6
• A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
• A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
• A61K 31/455 - Acide nicotinique, c.-à-d. niacineSes dérivés, p. ex. esters, amides
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/07 - Composés du rétinol, p. ex. vitamine A
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 31/51 - Thiamines, p. ex. vitamine B1
• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
• A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A23L 33/175 - Acides aminés
• A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
• A23L 33/155 - Vitamines A ou D
• A23L 33/22 - Parties fibreuses broyées de plantes, p. ex. bagasse ou pulpe

Abrégé

Disclosed is a formulation which, associated with a grinding system, transforms biohazardous infectious waste (RPBI) into raw material for producing compost, allowing biohazardous infectious waste to be inactivated for use and industrial biohazardous infectious waste to be inactivated for reuse as a protein source for producing protein products. The formulation can be used to eliminate microorganisms in waste resulting from the production of drugs and vaccines in ovo, with applications in biohazardous infectious waste and animal waste with a high protein content and decomposition potential, for compost production.

Classes IPC  ?

• A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
• A61L 11/00 - Procédés de désinfection ou de stérilisation spécialement adaptés aux déchets
• A01N 31/02 - Composés acycliques

Abrégé

The present invention relates to the field of medicaments that reduce cardiac fibrosis and also the expression of troponin I, specifically to the pharmaceutical use containing 5-methyl-1-phenyl-2-(1H)-pyridone (Pirfenidone) as an active ingredient, alone or in combination with any other bioactive molecule, specifically for the management of patients with cardiomyopathy and/or cardiac steatosis and/or COVID-19.

Classes IPC  ?

• A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

Classes IPC  ?

• A61B 3/12 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p. ex. ophtalmoscopes
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
• G06T 3/40 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement
• G06T 3/60 - Rotation d’images entières ou de parties d'image

Abrégé

Gastritis is the inflammation of the gastric mucosa. It affects around 50% of the world population and its main etiology is the chronic consumption of non-steroidal anti-inflammatories and infection by Helicobacter pylori, in addition to an increase in acid-secreting cells. This gastric disease is characterised by the presence of polymorphonuclear cell infiltrate; an overexpression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin 1 beta (IL-1b), interleukin 6 (IL-6); and hyperactivity of cyclooxygenase 2 (COX-2) and its downstream product prostaglandin E2 (PGE2), which causes inflammation in the stomach. The invention developed aims to provide a supplement of capsaicin and sulforaphane in combination with any type of prebiotics and/or probiotics, preferably contained in a capsule for use as an anti-inflammatory, anti-fibrotic, and analgesic coadjuvant for inflammation of the gastric mucosa, gastritis caused by different agents.

Classes IPC  ?

• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The invention relates to a pharmaceutical composition for the treatment of diseases that occur with fibrosis in any type of tissue, comprising a gene vector containing the construct including an shRNA for regulating the expression of cannabinoid receptor type-1 (CB1) as an anti-fibrotic strategy.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

Classes IPC  ?

• A23L 33/19 - Protéines du lait
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/12 - Acides gras ou leurs dérivés
• A23L 33/155 - Vitamines A ou D

Abrégé

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/15 - Vitamines

Abrégé

The purpose of the invention is to provide the use of 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone) and chitosan in an ophthalmic solution for preventing the development of corneal opacity following refractive ophthalmic surgery with an excimer laser. Every 100 mL of the ophthalmic solution contains 0.1-1.5 g pirfenidone, 0.5-2 g chitosan, 0.5 g povidone, 5 g Kolliphor® HS 15, 0.6-0.62 g boric acid, 0.5-0.9 g sodium chloride, 0.5 g chlorobutanol and injectable water. The pH of the ophthalmic solution is 6.5-7. On the basis of the experiments conducted on the developed formulation, it is observed that both chitosan plus pirfenidone, and prednisolone are able to reverse corneal damage once corneal damage has been established.

Classes IPC  ?

• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61K 31/722 - ChitineChitosane
• A61P 27/02 - Agents ophtalmiques

Abrégé

Diabetes is a disease characterised by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Oedema (DMO), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 3/12 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p. ex. ophtalmoscopes
• G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume

Abrégé

322244). The formulation obtained can be applied to infectious, hazardous biological residues in hospital waste, medical devices without metal parts, haemodialysis filters, laser crystal tips, medical instruments made from plastic, elastomers and stainless steel, water treatment, food handling and hygiene, disinfection of grey and white areas in hospitals, laboratories and clinics, disinfection of fruit and vegetables. As such, the range of application of the formulation is broad.

Classes IPC  ?

• A01N 37/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe Leurs thio-analogues
• A61L 2/16 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques
• A61K 8/22 - PeroxydesOxygèneOzone

Abrégé

Vaccinium myrtillus LVaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

Classes IPC  ?

• A61K 31/07 - Composés du rétinol, p. ex. vitamine A
• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
• A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
• A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
• A61P 27/02 - Agents ophtalmiques

Abrégé

The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

Classes IPC  ?

• A61K 31/07 - Composés du rétinol, p. ex. vitamine A
• A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
• A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
• A61P 27/02 - Agents ophtalmiques